SCHEMBL7799220

SCHEMBL7799220

COc1cc2cnc(Nc3cccc(Br)c3)nc2cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.65
EGFR P00533 14/20 0.56
ERBB2 P04626 7/20 0.56
GAK O14976 3/20 0.56
FBP1 P09467 3/20 0.56
KDR P35968 2/20 0.56
TNF P01375 1/20 0.56
KDM4E B2RXH2 1/20 0.56
MAPK13 O15264 1/20 0.56
ABL1 P00519 1/20 0.56
CYP1A2 P05177 1/20 0.56
CDK1 P06493 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
MAPT P10636 1/20 0.56
CYP2C9 P11712 1/20 0.56
SRC P12931 1/20 0.56
TSHR P16473 1/20 0.56
MAPK1 P28482 1/20 0.56
EPHB2 P29323 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7524075 0.90 ABCG2 (0.54) ABCG2EGFRERBB2GAKFBP1
SCHEMBL5909044 0.88 FBP1 (0.58) ABCG2EGFRERBB2GAKFBP1
SCHEMBL7757002 0.85 PDGFRB (0.59) EGFRKDRKDM4ECDK1MAPT
SCHEMBL7753469 0.85 FGFR1 (0.56) ABCG2EGFRERBB2KDRMAPT
SCHEMBL28221880 0.85 PDGFRB (0.64) ABCG2EGFRERBB2FBP1TNF
SCHEMBL7800405 0.85 EGFR (0.56) ABCG2EGFRERBB2FBP1KDM4E
SCHEMBL8812882 0.83 PDGFRB (0.57) EGFRKDRKDM4ECDK1MAPT
SCHEMBL7801689 0.81 ABCG2 (0.67) ABCG2EGFRERBB2KDM4EMAPT
SCHEMBL7754110 0.81 EGFR (0.54) ABCG2EGFRERBB2KDRKDM4E
SCHEMBL1246693 0.80 ABCG2 (0.58) ABCG2EGFRERBB2KDRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1162974-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP disclosed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed